В России допустили принятие резолюции Совбеза ООН по Украине02:49
Another important reform would be reducing regulatory opacity. The requirements that the U.S. Food and Drug Administration (FDA) applies to manufacturing and trial design are often interpreted through informal guidance, case-by-case feedback, and evolving expectations. This lack of transparency and consistency can distort the market, forcing companies to overbuild processes, hire expensive regulatory consultants, or pursue unnecessarily conservative strategies simply to avoid the risk of rejection. In many cases, the uncertainty created by opaque regulation imposes greater costs than the regulation itself. Greater clarity, standardized guidance, and more predictable decision-making could therefore significantly reduce development costs without weakening safety oversight.
。关于这个话题，易歪歪下载官网提供了深入分析
WorkBuddy 是什么、不是什么
"But we now have hope that the regime will soon be gone. We are happy."